Related Experiment Video

Updated: Jun 23, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells

Aiyu Gong1, Meilan He, Donkena Krishna Vanaja

  • 1Department of Urology, and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905 USA.

Molecular Nutrition & Food Research
|May 14, 2009
PubMed

Insights

Phenethyl isothiocyanate (PEITC) from cruciferous vegetables inhibits prostate cancer cell growth by blocking the IL-6/JAK/STAT3 pathway. This mechanism involves reducing cellular reactive oxygen species (ROS) production.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer remains a significant health concern.
  • Natural compounds offer potential therapeutic avenues.
  • The IL-6/JAK/STAT3 pathway is implicated in cancer progression.

Purpose of the Study:

  • To elucidate the antitumor mechanism of phenethyl isothiocyanate (PEITC) in prostate cancer.
  • To investigate PEITC's effect on the IL-6/JAK/STAT3 signaling pathway.
  • To determine the role of reactive oxygen species (ROS) in PEITC's action.

Main Methods:

  • Cell proliferation and cell cycle assays were performed.
  • Western blot analysis was used to assess protein phosphorylation.
  • Gene transfer and reporter assays evaluated pathway activity.
  • The impact of N-acetyl-L-cysteine (NAC) was examined.

Main Results:

  • PEITC inhibited prostate cancer cell proliferation and induced G2-M phase arrest.
  • PEITC suppressed both constitutive and IL-6-induced STAT3 activation.
  • PEITC attenuated IL-6-stimulated JAK2 phosphorylation.
  • NAC reversed PEITC's inhibitory effects on proliferation and JAK-STAT3 signaling.

Conclusions:

  • PEITC exhibits antitumor effects against prostate cancer cells.
  • PEITC inhibits the JAK-STAT3 signaling cascade.
  • Blocking cellular ROS production is a potential mechanism for PEITC's action.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...